Log In
BCIQ
Print this Print this
 

GSK2285921, LGD-4665

Also known as: formerly LGD4665

  Manage Alerts
Collapse Summary General Information
Company Ligand Pharmaceuticals Inc.
DescriptionOral thrombopoietin (TPO) mimic
Molecular Target Thrombopoietin (TPO) receptor (CD110) (Mpl)
Mechanism of ActionThrombopoietin (TPO) receptor (CD110) (Mpl) agonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationThrombocytopenia
Indication DetailsTreat chemotherapy-induced and liver disease-induced thrombocytopenia; Treat diseases associated with thrombocytopenia; Treat thrombocytopenia
Regulatory Designation
PartnerGlaxoSmithKline plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today